Symbols / FLGT
FLGT Chart
About
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 713.77M |
| Enterprise Value | 340.82M | Income | -42.98M | Sales | 315.55M |
| Book/sh | 36.49 | Cash/sh | 12.16 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1313 | IPO | — |
| P/E | — | Forward P/E | -72.14 | PEG | — |
| P/S | 2.26 | P/B | 0.63 | P/C | — |
| EV/EBITDA | -7.28 | EV/Sales | 1.08 | Quick Ratio | 6.28 |
| Current Ratio | 7.00 | Debt/Eq | 0.71 | LT Debt/Eq | — |
| EPS (ttm) | -1.41 | EPS next Y | -0.32 | EPS Growth | — |
| Revenue Growth | 17.20% | Earnings | 2026-02-27 | ROA | -3.62% |
| ROE | -3.92% | ROIC | — | Gross Margin | 41.24% |
| Oper. Margin | -18.26% | Profit Margin | -13.62% | Shs Outstand | 30.91M |
| Shs Float | 20.42M | Short Float | 9.93% | Short Ratio | 8.68 |
| Short Interest | — | 52W High | 31.04 | 52W Low | 14.57 |
| Beta | 0.87 | Avg Volume | 210.96K | Volume | 267.64K |
| Target Price | $33.67 | Recom | None | Prev Close | $23.01 |
| Price | $23.09 | Change | 0.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$33.67
Mean price target
2. Current target
$23.09
Latest analyst target
3. DCF / Fair value
$-11.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$23.09
Low
$30.00
High
$36.00
Mean
$33.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-11 | main | Piper Sandler | Neutral → Neutral | $30 |
| 2025-08-05 | up | UBS | Neutral → Buy | $30 |
| 2025-08-04 | main | Piper Sandler | Neutral → Neutral | $21 |
| 2025-05-06 | main | Piper Sandler | Neutral → Neutral | $23 |
| 2025-05-05 | reit | Raymond James | Outperform → Outperform | $25 |
| 2025-03-04 | main | Piper Sandler | Neutral → Neutral | $16 |
| 2024-11-11 | main | Piper Sandler | Neutral → Neutral | $22 |
| 2024-03-06 | main | Piper Sandler | Neutral → Neutral | $25 |
| 2023-12-07 | init | UBS | — → Neutral | $35 |
| 2023-10-16 | main | Piper Sandler | Neutral → Neutral | $28 |
| 2023-03-02 | main | Credit Suisse | — → Outperform | $45 |
| 2022-12-08 | down | Piper Sandler | Overweight → Neutral | $40 |
| 2022-11-18 | init | Raymond James | — → Outperform | $45 |
| 2022-11-14 | main | Credit Suisse | — → Outperform | $50 |
| 2022-11-14 | main | Piper Sandler | — → Overweight | $65 |
| 2022-08-25 | init | Credit Suisse | — → Outperform | $65 |
| 2022-05-16 | main | Piper Sandler | — → Overweight | $70 |
| 2022-01-25 | main | Oppenheimer | — → Outperform | $125 |
| 2021-08-10 | main | Credit Suisse | — → Underperform | $65 |
| 2021-03-05 | main | Piper Sandler | — → Overweight | $140 |
- Price-Driven Insight from (FLGT) for Rule-Based Strategy - Stock Traders Daily ue, 24 Feb 2026 19
- Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock - Seeking Alpha ue, 27 Jan 2026 08
- Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Zacks Research - MarketBeat Wed, 11 Feb 2026 08
- $FLGT stock is up 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 07 Nov 2025 08
- Why Fulgent Genetics Stock Was Crushing It on Friday - The Motley Fool Fri, 01 Aug 2025 07
- Aug Chart Watch: Whats the fair value of FLGT stock - July 2025 Levels & Weekly High Potential Stock Alerts - baoquankhu1.vn ue, 24 Feb 2026 00
- Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price Is Out Of Tune With Revenues - simplywall.st Sat, 08 Nov 2025 08
- Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance Fri, 01 Aug 2025 07
- Earnings call transcript: Fulgent Genetics Q3 2025 Surpasses EPS Expectations - Investing.com Fri, 07 Nov 2025 08
- Fulgent Genetics (FLGT) Projected to Post Earnings on Friday - MarketBeat Fri, 20 Feb 2026 08
- Fulgent Genetics, Inc.'s (NASDAQ:FLGT) institutional investors lost 6.9% last week but have benefitted from longer-term gains - Sahm Fri, 30 Jan 2026 08
- FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform - Zacks Investment Research ue, 23 Dec 2025 08
- Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy) - Seeking Alpha Mon, 08 Sep 2025 07
- (FLGT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily Mon, 02 Feb 2026 16
- Fulgent Genetics: A Risky Bet or a Hidden Gem? - The Motley Fool hu, 11 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1140 | 32298 | — | Sale at price 28.33 per share. | XIE JIAN | President | — | 2025-12-02 00:00:00 | D |
| 1 | 1075 | 30457 | — | Sale at price 28.33 per share. | GAO HANLIN | Officer | — | 2025-12-02 00:00:00 | D |
| 2 | 1198 | 35424 | — | Sale at price 29.57 per share. | XIE JIAN | President | — | 2025-11-28 00:00:00 | D |
| 3 | 943 | 27884 | — | Sale at price 29.57 per share. | GAO HANLIN | Officer | — | 2025-11-28 00:00:00 | D |
| 4 | 681 | 20752 | — | Sale at price 30.47 per share. | XIE JIAN | President | — | 2025-11-24 00:00:00 | D |
| 5 | 535 | 16303 | — | Sale at price 30.47 per share. | GAO HANLIN | Officer | — | 2025-11-24 00:00:00 | D |
| 6 | 10000 | — | — | Stock Gift at price 0.00 per share. | XIE JIAN | President | — | 2025-11-19 00:00:00 | D |
| 7 | 10000 | 290983 | — | Sale at price 29.10 per share. | XIE JIAN | President | — | 2025-11-19 00:00:00 | D |
| 8 | 1128 | 24846 | — | Sale at price 22.03 per share. | XIE JIAN | President | — | 2025-09-03 00:00:00 | D |
| 9 | 1063 | 23414 | — | Sale at price 22.03 per share. | GAO HANLIN | Officer | — | 2025-09-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.62M | -25.25M | -675.33K | 0.00 |
| TaxRateForCalcs | 0.16 | 0.21 | 0.23 | 0.26 |
| NormalizedEBITDA | -38.92M | -27.22M | 220.68M | 686.96M |
| TotalUnusualItems | -10.07M | -120.23M | -2.98M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -10.07M | -120.23M | -2.98M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -42.71M | -167.82M | 143.40M | 507.36M |
| ReconciledDepreciation | 24.93M | 26.14M | 32.66M | 11.00M |
| ReconciledCostOfRevenue | 159.29M | 166.46M | 225.90M | 206.24M |
| EBITDA | -48.99M | -147.45M | 217.70M | 686.96M |
| EBIT | -73.92M | -173.60M | 185.04M | 675.95M |
| NetInterestIncome | 31.47M | 21.12M | 4.61M | 1.35M |
| InterestExpense | 488.00K | 1.01M | ||
| InterestIncome | 31.47M | 21.61M | 5.62M | 1.35M |
| NormalizedIncome | -34.26M | -72.84M | 145.70M | 507.36M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -42.71M | -167.82M | 143.40M | 507.36M |
| TotalExpenses | 357.39M | 364.51M | 437.47M | 316.63M |
| TotalOperatingIncomeAsReported | -73.92M | -195.53M | 178.53M | 675.95M |
| DilutedAverageShares | 30.23M | 29.78M | 30.96M | 30.98M |
| BasicAverageShares | 30.23M | 29.78M | 30.10M | 29.41M |
| DilutedEPS | -1.41 | -5.63 | 4.63 | 16.38 |
| BasicEPS | -1.41 | -5.63 | 4.76 | 17.25 |
| DilutedNIAvailtoComStockholders | -42.71M | -167.82M | 143.40M | 507.36M |
| NetIncomeCommonStockholders | -42.71M | -167.82M | 143.40M | 507.36M |
| NetIncome | -42.71M | -167.82M | 143.40M | 507.36M |
| MinorityInterests | 1.11M | 7.41M | 1.48M | 1.12M |
| NetIncomeIncludingNoncontrollingInterests | -43.82M | -175.24M | 141.92M | 506.24M |
| NetIncomeContinuousOperations | -43.82M | -175.24M | 141.92M | 506.24M |
| EarningsFromEquityInterestNetOfTax | 0.00 | 0.00 | 3.73M | |
| TaxProvision | -8.14M | 1.15M | 42.10M | 174.79M |
| PretaxIncome | -51.96M | -174.09M | 184.03M | 677.30M |
| OtherIncomeExpense | -9.51M | -119.91M | -2.09M | |
| OtherNonOperatingIncomeExpenses | 561.00K | 320.00K | 887.00K | |
| SpecialIncomeCharges | -10.07M | -120.23M | -2.98M | 0.00 |
| WriteOff | 10.07M | 0.00 | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 120.23M | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | 2.98M | 0.00 |
| NetNonOperatingInterestIncomeExpense | 31.47M | 21.12M | 4.61M | 1.35M |
| InterestExpenseNonOperating | 488.00K | 1.01M | ||
| InterestIncomeNonOperating | 31.47M | 21.61M | 5.62M | 1.35M |
| OperatingIncome | -73.92M | -75.30M | 181.50M | 675.95M |
| OperatingExpense | 181.13M | 179.75M | 185.40M | 101.10M |
| DepreciationAmortizationDepletionIncomeStatement | 7.96M | 7.84M | 6.50M | 1.71M |
| DepreciationAndAmortizationInIncomeStatement | 7.96M | 7.84M | 6.50M | 1.71M |
| Amortization | 7.96M | 7.84M | 6.50M | 1.71M |
| AmortizationOfIntangiblesIncomeStatement | 7.96M | 7.84M | 6.50M | 1.71M |
| ResearchAndDevelopment | 48.82M | 41.44M | 28.91M | 24.22M |
| SellingGeneralAndAdministration | 124.35M | 130.47M | 149.99M | 75.17M |
| SellingAndMarketingExpense | 36.25M | 41.47M | 38.92M | 24.44M |
| GeneralAndAdministrativeExpense | 88.11M | 89.00M | 111.07M | 50.73M |
| OtherGandA | 88.11M | 89.00M | 111.07M | 50.73M |
| SalariesAndWages | 3.48M | |||
| GrossProfit | 107.22M | 104.46M | 366.90M | 777.05M |
| CostOfRevenue | 176.25M | 184.76M | 252.07M | 215.53M |
| TotalRevenue | 283.47M | 289.21M | 618.97M | 992.58M |
| OperatingRevenue | 283.47M | 289.21M | 618.97M | 992.58M |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 2.77M | 2.76M | ||
| OrdinarySharesNumber | 30.84M | 29.65M | 29.44M | 30.16M |
| ShareIssued | 33.61M | 32.42M | 29.44M | 30.16M |
| TotalDebt | 8.47M | 15.25M | 38.94M | 21.28M |
| TangibleBookValue | 976.20M | 970.99M | 973.01M | 1.07B |
| InvestedCapital | 1.14B | 1.14B | 1.29B | 1.18B |
| WorkingCapital | 280.67M | 434.83M | 539.77M | 506.65M |
| NetTangibleAssets | 976.20M | 970.99M | 973.01M | 1.07B |
| CapitalLeaseObligations | 5.56M | 11.10M | 14.93M | |
| CommonStockEquity | 1.13B | 1.14B | 1.27B | 1.16B |
| TotalCapitalization | 1.14B | 1.14B | 1.27B | 1.16B |
| TotalEquityGrossMinorityInterest | 1.13B | 1.13B | 1.27B | 1.17B |
| MinorityInterest | -4.07M | -2.81M | 3.19M | 7.13M |
| StockholdersEquity | 1.13B | 1.14B | 1.27B | 1.16B |
| GainsLossesNotAffectingRetainedEarnings | -368.00K | 1.21M | -20.90M | -759.00K |
| OtherEquityAdjustments | -368.00K | 1.21M | -20.90M | -759.00K |
| RetainedEarnings | 590.47M | 633.17M | 801.00M | 657.60M |
| AdditionalPaidInCapital | 543.13M | 501.72M | 486.58M | 501.91M |
| CapitalStock | 3.00K | 3.00K | 3.00K | 3.00K |
| CommonStock | 3.00K | 3.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 90.81M | 102.04M | 116.18M | 112.84M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 17.91M | 29.02M | 28.07M | 7.53M |
| OtherNonCurrentLiabilities | 4.92M | 10.95M | 15.90M | 7.53M |
| NonCurrentDeferredLiabilities | 6.37M | 7.96M | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 6.37M | 7.96M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 6.61M | 10.11M | 12.17M | |
| LongTermCapitalLeaseObligation | 4.12M | 7.15M | 8.79M | |
| LongTermDebt | 2.49M | 2.96M | 3.37M | |
| CurrentLiabilities | 72.90M | 73.02M | 88.11M | 105.31M |
| OtherCurrentLiabilities | 164.00K | 5.30M | 10.68M | |
| CurrentDeferredLiabilities | 29.84M | 25.57M | 14.09M | 34.38M |
| CurrentDeferredRevenue | 29.84M | 25.57M | 14.09M | 34.38M |
| CurrentDebtAndCapitalLeaseObligation | 1.85M | 5.14M | 26.77M | 21.28M |
| CurrentCapitalLeaseObligation | 1.44M | 3.96M | 6.13M | |
| CurrentDebt | 412.00K | 1.18M | 20.64M | 21.28M |
| OtherCurrentBorrowings | 412.00K | 1.18M | 20.64M | 15.14M |
| CurrentNotesPayable | 5.64M | 6.15M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.80M | 6.25M | ||
| PayablesAndAccruedExpenses | 35.40M | 35.88M | 41.94M | 38.97M |
| CurrentAccruedExpenses | 17.03M | 20.52M | 18.85M | 17.69M |
| Payables | 18.36M | 15.36M | 23.09M | 21.28M |
| TotalTaxPayable | 0.00 | 787.00K | ||
| IncomeTaxPayable | 0.00 | 787.00K | ||
| AccountsPayable | 18.36M | 15.36M | 23.09M | 20.49M |
| TotalAssets | 1.22B | 1.24B | 1.39B | 1.28B |
| TotalNonCurrentAssets | 866.39M | 727.48M | 758.18M | 666.76M |
| OtherNonCurrentAssets | 33.46M | 34.90M | 44.12M | 10.65M |
| InvestmentsAndAdvances | 570.35M | 444.01M | 339.03M | 507.01M |
| OtherInvestments | 12.38M | 21.96M | ||
| InvestmentinFinancialAssets | 570.35M | 444.01M | 339.03M | 507.01M |
| AvailableForSaleSecurities | 570.35M | 444.01M | 339.03M | 507.01M |
| GoodwillAndOtherIntangibleAssets | 157.03M | 165.11M | 293.67M | 86.81M |
| OtherIntangibleAssets | 134.98M | 143.05M | 150.64M | 35.91M |
| Goodwill | 22.05M | 22.05M | 143.03M | 50.90M |
| NetPPE | 105.55M | 83.46M | 81.35M | 62.29M |
| AccumulatedDepreciation | -51.71M | -51.63M | -43.28M | -19.63M |
| GrossPPE | 157.26M | 135.10M | 124.63M | 81.92M |
| Leases | 3.32M | 11.22M | 11.80M | 4.00M |
| OtherProperties | 60.44M | 71.15M | 66.42M | 42.69M |
| MachineryFurnitureEquipment | 25.63M | 25.49M | 25.41M | 16.65M |
| BuildingsAndImprovements | 49.61M | 17.53M | 12.60M | 10.67M |
| LandAndImprovements | 18.25M | 9.70M | 8.40M | 7.90M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 353.57M | 507.85M | 627.87M | 611.96M |
| PrepaidAssets | 10.05M | 20.42M | 22.25M | 5.96M |
| Inventory | 8.38M | 5.83M | 4.28M | 12.21M |
| RawMaterials | 8.38M | 5.83M | 4.28M | 12.21M |
| Receivables | 77.03M | 57.45M | 75.11M | 143.29M |
| OtherReceivables | 1.77M | 1.32M | 19.84M | 1.64M |
| AccruedInterestReceivable | 6.24M | 4.99M | 2.52M | 2.74M |
| AccountsReceivable | 69.02M | 51.13M | 52.75M | 138.91M |
| AllowanceForDoubtfulAccountsReceivable | -20.46M | -25.23M | -41.20M | -11.22M |
| GrossAccountsReceivable | 89.48M | 76.36M | 93.95M | 150.13M |
| CashCashEquivalentsAndShortTermInvestments | 258.11M | 424.15M | 526.24M | 450.50M |
| OtherShortTermInvestments | 202.96M | 326.68M | 446.73M | 285.61M |
| CashAndCashEquivalents | 55.14M | 97.47M | 79.51M | 164.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.25M | 4.80M | 234.75M | 514.73M |
| RepurchaseOfCapitalStock | -3.12M | -27.79M | -76.11M | -4.16M |
| RepaymentOfDebt | -1.77M | -20.00M | -1.07M | -11.00K |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | 0.00 | 89.47M | |
| CapitalExpenditure | -40.31M | -22.21M | -18.77M | -23.84M |
| InterestPaidSupplementalData | 512.00K | 960.00K | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 27.59M | 3.26M | 56.19M | 237.07M |
| EndCashPosition | 55.28M | 97.47M | 79.51M | 164.89M |
| BeginningCashPosition | 97.47M | 79.51M | 164.89M | 87.43M |
| EffectOfExchangeRateChanges | -55.00K | -149.00K | -453.00K | 34.00K |
| ChangesInCash | -42.14M | 18.12M | -84.94M | 77.43M |
| FinancingCashFlow | -4.85M | -47.78M | -77.14M | 85.41M |
| CashFlowFromContinuingFinancingActivities | -4.85M | -47.78M | -77.14M | 85.41M |
| NetOtherFinancingCharges | -15.00M | -1.77M | 10.00K | |
| ProceedsFromStockOptionExercised | 51.00K | 3.00K | 31.00K | 86.00K |
| NetCommonStockIssuance | -3.12M | -27.79M | -76.11M | 85.32M |
| CommonStockPayments | -3.12M | -27.79M | -76.11M | -4.16M |
| CommonStockIssuance | 0.00 | 0.00 | 89.47M | |
| NetIssuancePaymentsOfDebt | -1.77M | -20.00M | -1.07M | -11.00K |
| NetShortTermDebtIssuance | -1.23M | -19.27M | -367.00K | -4.00K |
| ShortTermDebtPayments | -1.23M | -19.27M | -367.00K | -4.00K |
| ShortTermDebtIssuance | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | -544.00K | -730.00K | -700.00K | -7.00K |
| LongTermDebtPayments | -544.00K | -730.00K | -700.00K | -7.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -58.35M | 38.90M | -261.31M | -546.55M |
| CashFlowFromContinuingInvestingActivities | -58.35M | 38.90M | -261.31M | -546.55M |
| NetInvestmentPurchaseAndSale | -18.35M | 60.73M | -60.27M | -460.90M |
| SaleOfInvestment | 454.06M | 552.64M | 372.71M | 269.59M |
| PurchaseOfInvestment | -472.42M | -491.91M | -432.98M | -730.49M |
| NetBusinessPurchaseAndSale | 0.00 | -399.00K | -182.68M | -61.87M |
| PurchaseOfBusiness | 0.00 | -399.00K | -182.68M | -61.87M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -32.00K | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -32.00K | |
| NetPPEPurchaseAndSale | -40.00M | -21.43M | -18.36M | -23.75M |
| SaleOfPPE | 313.00K | 775.00K | 412.00K | 63.00K |
| PurchaseOfPPE | -40.31M | -22.21M | -18.77M | -23.81M |
| OperatingCashFlow | 21.06M | 27.00M | 253.52M | 538.58M |
| CashFlowFromContinuingOperatingActivities | 21.06M | 27.00M | 253.52M | 538.58M |
| ChangeInWorkingCapital | -7.24M | 2.84M | 2.00M | -2.68M |
| ChangeInOtherWorkingCapital | 13.53M | 14.25M | -34.93M | |
| ChangeInOtherCurrentLiabilities | -3.77M | -6.29M | -4.83M | -1.12M |
| ChangeInOtherCurrentAssets | 199.00K | -3.33M | 9.38M | 7.80M |
| ChangeInPayablesAndAccruedExpense | -895.00K | -4.18M | -36.25M | -51.66M |
| ChangeInAccruedExpense | -3.96M | 2.72M | -10.91M | 13.08M |
| ChangeInPayable | 3.07M | -6.90M | -25.34M | -64.74M |
| ChangeInAccountPayable | 3.07M | -6.90M | -25.34M | -12.21M |
| ChangeInTaxPayable | 0.00 | -827.00K | -52.53M | |
| ChangeInIncomeTaxPayable | 0.00 | -827.00K | -52.53M | |
| ChangeInReceivables | -16.30M | 2.39M | 68.64M | 42.30M |
| ChangesInAccountReceivables | -16.30M | 2.39M | 68.64M | 42.30M |
| OtherNonCashItems | 3.75M | 6.39M | 4.90M | 1.14M |
| StockBasedCompensation | 44.48M | 42.92M | 32.64M | 15.88M |
| ProvisionandWriteOffofAssets | -1.73M | -880.00K | 32.60M | 8.93M |
| AssetImpairmentCharge | 10.07M | 120.23M | 0.00 | 0.00 |
| AmortizationOfSecurities | -5.55M | -3.91M | 4.77M | 7.60M |
| DeferredTax | -5.15M | 7.61M | 831.00K | -7.84M |
| DeferredIncomeTax | -5.15M | 7.61M | 831.00K | -7.84M |
| DepreciationAmortizationDepletion | 24.93M | 26.14M | 32.66M | 11.00M |
| DepreciationAndAmortization | 24.93M | 26.14M | 32.66M | 11.00M |
| OperatingGainsLosses | 1.31M | 894.00K | 1.19M | -1.70M |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | ||
| GainLossOnInvestmentSecurities | 994.00K | 589.00K | 692.00K | 1.19M |
| GainLossOnSaleOfPPE | 320.00K | 305.00K | 502.00K | 850.00K |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | -3.73M | |
| NetIncomeFromContinuingOperations | -43.82M | -175.24M | 141.92M | 506.24M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FLGT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|